Purchase Order 75N90025P00611

Award Date 8/6/25
Potential Completion Date 9/5/25
Potential Value $25K
Federal Agency
NIH Clinical Center
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $97,722.00 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's research initiatives, with a completion date of September 19, 2025. This contract is not designated as a set-aside....
This $8,435.16 firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services' National Institutes of Health, to Genscript USA Inc., a for-profit biotechnology company located in Piscataway, New Jersey. The contract is for antibody production services, with a completion date of June 15, 2018. Genscript specializes in providing a range of biomedical research and public health products and services to...
This firm fixed-price purchase order, valued at $16,215, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has received numerous prime...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $164,700.00 firm fixed-price purchase order is for monoclonal antibodies and plasmids services, with a completion date of June 14, 2026. The contract does not have a set-aside designation. Genscript is a key supplier of...
This is a $164,700 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support critical research initiatives, with a period of performance through June 15, 2026. While the contract does not have a set-aside...
This is a $10,417.90 firm fixed-price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), an agency within the U.S. Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The contract is for the provision of custom/monoclonal antibodies to support NICHD's biomedical research and public health initiatives. Genscript, which specializes in gene synthesis, protein production,...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $3,800.00, is for custom monoclonal antibody production services to support NIAID's biomedical research and public health initiatives. This contract does not have a set-aside designation. Genscript...
This is a $29,998.04 firm fixed price purchase order awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The contract is for the production and purification of recombinant human antibodies against influenza A, which will support the mission of NIAID's Cellular Biology Section. This sole-source award was justified under the authority of FAR...
This contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, provides Genscript USA Inc. with $137,250.00 to deliver monoclonal antibodies and plasmid services. The firm-fixed price purchase order has an ultimate completion date of August 31, 2025. Genscript USA Inc. is a biotechnology company in Piscataway, New Jersey that specializes in molecular biology products and services for federal agencies....
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed price purchase order to GenScript USA Inc., a for-profit biotechnology company, to provide custom monoclonal antibody production services. The $13,758.30 contract has an October 16, 2019 completion date and was awarded on August 14, 2019. GenScript, based in Piscataway, New Jersey, specializes in gene synthesis, protein production, and other...

This is a $24,564.70 firm-fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for antibody fragment humanization services, which involves modifying antibody proteins to make them more suitable for human therapeutic use.

The contract does not have a set-aside designation. Genscript has a history of providing specialized molecular biology services, including gene synthesis, protein production, and antibody development, to federal agencies like the NIH, CDC, and USDA. This contract represents Genscript's continued support for federal biomedical research initiatives, particularly in the areas of infectious disease and public health. The work will be performed at Genscript's facilities in Piscataway, New Jersey, and the contract has an ultimate completion date of September 5, 2025.

Generated 8/6/25, 10:04 AM